Search Result

Pathways Recommended:	MAPK/ERK Pathway

Results for "

cancer-related pathways

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Payload (1) Akt (1) Apoptosis (6) Bcl-2 Family (1) c-Myc (1) Caspase (3) CD73 (1) Cyclic GMP-AMP Synthase (1) Cytochrome P450 (2) DNA/RNA Synthesis (2) Drug Derivative (1) E1/E2/E3 Enzyme (1) EGFR (1) Epigenetic Reader Domain (1) Ferroptosis (2) FGFR (1) Glutathione Peroxidase (1) HDAC (1) IAP (1) IFNAR (1) JAK (1) JNK (1) Mitochondrial Metabolism (1) NF-κB (1) NO Synthase (1) Notch (1) NTPDase (1) p38 MAPK (2) PARP (3) PKC (1) PROTACs (2) Ras (2) STAT (2) STING (2) Survivin (1) Transmembrane Glycoprotein (2) VEGFR (1) Wnt (3) β-catenin (1)
By Research Areas:	Cancer (20) Inflammation/Immunology (1)

By Targets:

ADC Payload (1)

Akt (1)

Apoptosis (6)

Bcl-2 Family (1)

c-Myc (1)

Caspase (3)

CD73 (1)

Cyclic GMP-AMP Synthase (1)

Cytochrome P450 (2)

DNA/RNA Synthesis (2)

Drug Derivative (1)

E1/E2/E3 Enzyme (1)

EGFR (1)

Epigenetic Reader Domain (1)

Ferroptosis (2)

FGFR (1)

Glutathione Peroxidase (1)

HDAC (1)

IAP (1)

IFNAR (1)

JAK (1)

JNK (1)

Mitochondrial Metabolism (1)

NF-κB (1)

NO Synthase (1)

Notch (1)

NTPDase (1)

p38 MAPK (2)

PARP (3)

PKC (1)

PROTACs (2)

Ras (2)

STAT (2)

STING (2)

Survivin (1)

Transmembrane Glycoprotein (2)

VEGFR (1)

Wnt (3)

β-catenin (1)

By Research Areas:

Cancer (20)

Inflammation/Immunology (1)

Inhibitors & Agonists

Screening Libraries

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-175615

RSL3-NH2	ADC Payload Glutathione Peroxidase Ferroptosis	Cancer
RSL3-NH2 is a GPX4 inhibitor and ferroptosis inducer. RSL3-NH2 triggers the iron-dependent cell death pathway associated with lipid peroxidation by inhibiting GPX4 activity. RSL3-NH2 exhibits significant cytotoxicity against colorectal cancer cells and effectively induces their ferroptosis. RSL3-NH2 can serve as a ADC payload for synthesizing antibody-drug conjugates (ADC) and be used in colorectal cancer-related research .

HY-N10790

RA-V	Wnt c-Myc Notch	Cancer
RA-V is a cyclic hexapeptide. RA-V has activity against Wnt, Myc and Notch with IC₅₀ values of 50, 75, and 93 ng/mL, respectively. RA-V can be used for the research of cancer-related signaling pathways .

HY-12842

UC-112	IAP Survivin Apoptosis Caspase	Inflammation/Immunology Cancer
UC-112 is a XIAP inhibitor with anticancer activity. UC-112 selectively downregulates and degrades survivin via the ubiquitin-mediated proteasomal degradation pathway. UC-112 reduces XIAP levels in in vivo tumor models. UC-112 activates caspase-3/7 and caspase-9, and induces cancer cell apoptosis. UC-112 is applicable to studies on melanoma, prostate cancer and cancer-related research .

HY-W006230

Anthraflavic acid	Cytochrome P450	Cancer
Anthraflavic acid specifically inhibits the activity of cytochrome P-448 without affecting phenobarbital-induced cytochrome P-450 or NADPH-dependent cytochrome c reduction. Anthraflavic acid inhibits cytosolic metabolic pathways, blocks the microsomal and cytosolic activation of IQ, and reduces the metabolic activation level of Glu-P-I. Anthraflavic acid may exert anticancer activity by inhibiting the metabolic activation of chemical carcinogens. Anthraflavic acid is applicable to cancer-related research .

HY-150538

STAT3-IN-12 1 Publications Verification	STAT Apoptosis	Cancer
STAT3-IN-12 is a potent STAT3 signal inhibitor that can inhibit IL-6 induced JAK/STAT3 signalling pathway activation. STAT3-IN-12 inhibits cancer cell growth, migration, and induce cell apoptosis as well as cycle arrest. STAT3-IN-12 can be used in cancer-related research, such as hepatocellular carcinoma (HCC) and oesophageal carcinoma .

HY-P991196

Anti-CD24 Antibody (SWA11)	Transmembrane Glycoprotein	Cancer
Anti-CD24 Antibody (SWA11) is a human IgG1 monoclonal antibody targeting CD24, with high affinity and specificity for CD24-expressing tumor cells. Anti-CD24 Antibody (SWA11) triggers endocytosis, alters STAT3-dependent gene expression, regulates Src phosphorylation, and blocks CD24-mediated signaling pathways. Anti-CD24 Antibody (SWA11) is applicable to cancer-related research such as lung cancer and ovarian cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-173447

8-BuS-AMP	NTPDase CD73	Cancer
8-BuS-AMP is a NTPDase1 inhibitor and a CD73/CD39 inhibitor, with an IC₅₀ of 35 μM and a K_i value of 0.292 μM against human NTPDase1; its K_i values against human CD73 and CD39 are 1.19 μM and 0.847 μM, respectively. 8-BuS-AMP binds to the substrate-binding pockets of NTPDase1 and CD73 to effectively block the conversion of ATP and AMP to adenosine, thereby enhancing the activation and proliferation of human peripheral T lymphocytes. 8-BuS-AMP possesses excellent enzymatic hydrolysis resistance and metabolic stability, resists hydrolysis by multiple NTPDase subtypes, and shows no activity against P2Y1 and P2Y12 receptors. 8-BuS-AMP can be used in purinergic signaling pathway and cancer-related studies .

HY-162465

BDW568	STING IFNAR	Cancer
BDW568 is a selective STING ^A230 agonist with an EC₅₀ of 5.7 μM. BDW568 triggers the interferon signaling pathway and induces the expression of interferon-stimulated genes including MX1 and OAS1. BDW568 is applicable for cancer-related research .

HY-156850

ITF 3756	HDAC NF-κB	Cancer
ITF 3756 is a selective, orally active HDAC6 inhibitor. ITF 3756 antagonizes TNF-α-induced activation of the NF-κB pathway. ITF 3756 reduces PD-L1 expression on human monocytes and CD8 ⁺ T cells, and exhibits antitumor activity. ITF 3756 can be used in colon cancer-related research .

HY-162966

MS7829	Cyclic GMP-AMP Synthase PROTACs STING	Cancer
MS7829 is a deubiquitinase-targeting chimera (DUBTAC) that targets cGAS. MS7829 recruits OTUB1 to cGAS, binds covalently to OTUB1, stabilizes the protein abundance of cGAS, and activates the cGAS-STING-IRF3 innate immune signaling pathway in an OTUB1-dependent manner. MS7829 is applicable to cancer-related research .

HY-116692

Apoptosis inducer 34	Apoptosis Caspase Mitochondrial Metabolism PARP DNA/RNA Synthesis
Apoptosis inducer 34 (Compound 4) is a small molecule compound that induces apoptosis by directly activating the intrinsic apoptotic pathway. Apoptosis inducer 34 promotes Apaf-1 oligomerization to form mature apoptosomes, thereby activating caspase-9 and caspase-3. It significantly activates the apoptotic pathway in Jurkat cells by enhancing the cytochrome c-dependent apoptotic signaling pathway, inducing PARP cleavage and chromosomal DNA fragmentation. Furthermore, Apoptosis inducer 34 exhibits low toxicity to normal cells, demonstrating potential for selective targeting of cancer cells. Apoptosis inducer 34 is a promising candidate for studying cancer related to apoptotic pathways .

HY-152951

Palmostatin M	Ras	Cancer
Palmostatin M is a Ras signaling modulator that targets acyl-protein thioesterase 1 (APT1) and 2 (APT2) in cells, with an IC₅₀ of 2.5 nM for APT1. Palmostatin M interferes with the depalmitoylation cycle of Ras and downregulates the overall Ras signaling pathway. Palmostatin M can be used in cancer-related research .

HY-185413

β-Catenin modulator-9	β-catenin Wnt	Cancer
β-Catenin modulator-9 (Compound IIa-2075) is a β-Catenin modulator. β-Catenin modulator-9 specifically targets the activity of the stable β-catenin pool and inhibits the Wnt signaling pathway. β-Catenin modulator-9 can be used in cancer-related research .

HY-121511

EML631	Epigenetic Reader Domain Wnt	Cancer
EML631 is a SPIN1 inhibitor with a K_d of 3-7 μM. EML631 interacts with the second Tudor domain of SPIN1 and blocks its ability to read the H3K4me3 histone mark. EML631 inhibits the coactivator activity of SPIN1 in the Wnt signaling pathway and reduces the activity of Wnt response reporter genes. EML631 can be used in cancer-related research .

HY-W269285

H-D-Tpi-OH D-1,2,3,4-Tetrahydronorharman-3-carboxylic acid	Drug Derivative NO Synthase Cytochrome P450	Cancer
H-D-Tpi-OH (D-1,2,3,4-Tetrahydronorharman-3-carboxylic acid) is a tetrahydro-β-carboline derivative. H-D-Tpi-OH only slightly upregulates QR1, mildly inhibits the aromatase and NO synthesis pathways, and shows no significant in vitro anti-breast tumor proliferation activity. H-D-Tpi-OH can be used in cancer-related research .

HY-183252

ICA-1S	PKC Apoptosis Caspase PARP p38 MAPK JNK	Cancer
ICA-1S is a specific PKC-ι inhibitor. ICA-1S can inhibit MAPK/JNK signaling pathway and downregulate the levels of c-Jun and TNF-α. ICA-1S inhibits the proliferation of breast cancer cells. ICA-1S induces apoptosis of breast cancer cells. ICA-1S can be used in breast cancer-related research .

HY-181653

PROTAC SKP2 Degrader-1	PROTACs E1/E2/E3 Enzyme DNA/RNA Synthesis JAK STAT Apoptosis	Cancer
PROTAC SKP2 Degrader-1 is a PROTAC degrader targeting SKP2, with a K_d value of 6.28 μM. PROTAC SKP2 Degrader-1 induces targeted degradation of SKP2 via the ubiquitin-proteasome system. PROTAC SKP2 Degrader-1 stabilizes the expression of SOCS1 and regulates the expression of immunoproteasomes through the JAK/STAT pathway, thereby inhibiting tumor cell proliferation. PROTAC SKP2 Degrader-1 is applicable for cancer-related research .

HY-182005

EGFR/VEGFR2-IN-12	EGFR VEGFR	Cancer
EGFR/VEGFR2-IN-12 is a dual EGFR/VEGFR2 inhibitor, with an IC₅₀ value of 64 nM against human EGFR and an IC₅₀ value of 74 nM against human VEGFR2. EGFR/VEGFR2-IN-12 inhibits the phosphorylation of EGFR and VEGFR2, induces cell cycle arrest at the G₁/S phase, activates apoptotic pathways, promotes PARP-1 cleavage, exhibits low micromolar antiproliferative activity, and shows much higher selectivity for cancer cells than normal cells. EGFR/VEGFR2-IN-12 is applicable for cancer-related research .

HY-184250

FGFR-IN-28	FGFR p38 MAPK Akt Bcl-2 Family PARP Apoptosis Ferroptosis	Cancer
FGFR-IN-28 is a FGFR inhibitor with inhibitory activity against multiple subtypes of the FGFR family, with an IC₅₀ of 4.4 nM against FGFR4. FGFR-IN-28 inhibits kinase activity and phosphorylation processes, and blocks the downstream MAPK and AKT signaling pathways. FGFR-IN-28 induces cellular DNA damage, cell cycle arrest, apoptosis and ferroptosis, and reduces the adhesion, invasion and metastasis abilities of cancer cells. FGFR-IN-28 exhibits anti-tumor activity in in vitro experiments on colon cancer cells, and inhibits tumor growth in colon cancer xenograft models. FGFR-IN-28 can be used in colon cancer-related research .

HY-P992209

Anti-CD318/CDCP1 Antibody (25A11)	Transmembrane Glycoprotein	Cancer
Anti-CD318/CDCP1 Antibody (25A11) is an anti-CDCP1 antibody. Anti-CD318/CDCP1 Antibody (25A11) drives the internalization of antibody-CDCP1 complexes, inhibits cancer cell migration and invasion, and blocks downstream migration/invasion signaling pathways. When conjugated with saponin, Anti-CD318/CDCP1 Antibody (25A11) mediates the killing of prostate cancer cells. When conjugated with saponin, this antibody acts as an immunotoxin to inhibit the growth and metastasis of primary prostate tumors in mouse xenograft models. Anti-CD318/CDCP1 Antibody (25A11) is applicable to prostate cancer-related research .

HY-183625

PCA-IN-1	Ras	Cancer
PCA-IN-1 is a polyisoprenylated cysteinyl amide (PCA) inhibitor that acts on multiple KRAS mutant subtypes. PCA-IN-1 dissociates KRAS4B from its transport chaperones, prevents its localization to the plasma membrane, and blocks downstream oncogenic signaling pathways. PCA-IN-1 inhibits colony formation of KRAS-mutant lung cancer cells, induces sustained long-term growth inhibition, and suppresses cell migration. PCA-IN-1 is applicable to the research of KRAS-mutant lung cancer .

Cat. No.	Product Name

HY-L234

Nucleotide Metabolite Compound Library	82 compounds
Nucleotide metabolism is central to cancer aggressiveness, underpinning uncontrolled proliferation, chemotherapy resistance, immune evasion, and metastasis. It is transcriptionally regulated by oncogenes (e.g., MYC) and tumor suppressors (e.g., pRb). Nucleotide imbalance and nucleoside degradation further regulate cell state transitions, especially following replication stress. Additionally, secretion of nucleotides/nucleosides into the tumor microenvironment modulates immune responses and influences treatment efficacy. Therefore, nucleotide metabolites have roles in disease response and indication in cancer research, and can be utilized to develop cancer-related mechanisms and drugs. MCE can provide 82 metabolites produced by nucleotide metabolic pathways, which can be used for disease mechanism research and drug research.

Nucleotide Metabolite Compound Library

82 compounds

Nucleotide metabolism is central to cancer aggressiveness, underpinning uncontrolled proliferation, chemotherapy resistance, immune evasion, and metastasis. It is transcriptionally regulated by oncogenes (e.g., MYC) and tumor suppressors (e.g., pRb). Nucleotide imbalance and nucleoside degradation further regulate cell state transitions, especially following replication stress. Additionally, secretion of nucleotides/nucleosides into the tumor microenvironment modulates immune responses and influences treatment efficacy. Therefore, nucleotide metabolites have roles in disease response and indication in cancer research, and can be utilized to develop cancer-related mechanisms and drugs.

MCE can provide 82 metabolites produced by nucleotide metabolic pathways, which can be used for disease mechanism research and drug research.

HY-L074

Anti-Breast Cancer Compound Library	3,181 compounds
Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC). Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer. MCE supplies a unique collection of 3,181 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

Anti-Breast Cancer Compound Library

3,181 compounds

Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC).

Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer.

MCE supplies a unique collection of 3,181 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

HY-L075

Anti-Lung Cancer Compound Library	2,886 compounds
Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers. As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy. MCE offers a unique collection of 2,886 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.

Anti-Lung Cancer Compound Library

2,886 compounds

Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers.

As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy.

MCE offers a unique collection of 2,886 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.

Cat. No.	Product Name	Target	Research Area	Image

HY-P991196

Anti-CD24 Antibody (SWA11)	Transmembrane Glycoprotein	Cancer
Anti-CD24 Antibody (SWA11) is a human IgG1 monoclonal antibody targeting CD24, with high affinity and specificity for CD24-expressing tumor cells. Anti-CD24 Antibody (SWA11) triggers endocytosis, alters STAT3-dependent gene expression, regulates Src phosphorylation, and blocks CD24-mediated signaling pathways. Anti-CD24 Antibody (SWA11) is applicable to cancer-related research such as lung cancer and ovarian cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P992209

Anti-CD318/CDCP1 Antibody (25A11)	Transmembrane Glycoprotein	Cancer
Anti-CD318/CDCP1 Antibody (25A11) is an anti-CDCP1 antibody. Anti-CD318/CDCP1 Antibody (25A11) drives the internalization of antibody-CDCP1 complexes, inhibits cancer cell migration and invasion, and blocks downstream migration/invasion signaling pathways. When conjugated with saponin, Anti-CD318/CDCP1 Antibody (25A11) mediates the killing of prostate cancer cells. When conjugated with saponin, this antibody acts as an immunotoxin to inhibit the growth and metastasis of primary prostate tumors in mouse xenograft models. Anti-CD318/CDCP1 Antibody (25A11) is applicable to prostate cancer-related research .

RA-V	Cyclopeptides Rubiaceae Plants Source Classification Rubia cordifolia L.	Wnt c-Myc Notch
RA-V is a cyclic hexapeptide. RA-V has activity against Wnt, Myc and Notch with IC₅₀ values of 50, 75, and 93 ng/mL, respectively. RA-V can be used for the research of cancer-related signaling pathways .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks